Highlighting Overland Therapeutics’ GPRC5D/BCMA Dual CAR-T Clinical Data

By | 21 April 2026
  • Demonstrating early-stage clinical safety and efficacy performance to advance dual targeted cell therapies
  • Discussing next steps for dual CAR-T innovation for complex diseases